@article {7057,
	title = {Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial},
	journal = {The Lancet Haematology},
	volume = {3},
	year = {2016},
	note = {Cited By :1Export Date: 18 February 2017References: Kumar, S.K., Rajkumar, S.V., Dispenzieri, A., Improved survival in multiple myeloma and the impact of novel therapies (2008) Blood, 111, pp. 2516-2520;Kumar, S.K., Dispenzieri, A., Lacy, M.Q., Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients (2014) Leukemia, 28, pp. 1122-1128; 
Kumar, S.K., Therneau, T.M., Gertz, M.A., Clinical course of patients with relapsed multiple myeloma (2004) Mayo Clin Proc, 79, pp. 867-874; 
Kumar, S.K., Lee, J.H., Lahuerta, J.J., Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study (2012) Leukemia, 26, pp. 149-157; 
Catley, L., Weisberg, E., Kiziltepe, T., Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells (2006) Blood, 108, pp. 3441-3449; 
Kikuchi, J., Wada, T., Shimizu, R., Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma (2010) Blood, 116, pp. 406-417; 
Hideshima, T., Richardson, P.G., Anderson, K.C., Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma (2011) Mol Cancer Ther, 10, pp. 2034-2042; 
Ocio, E.M., Vilanova, D., Atadja, P., In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma (2010) Haematologica, 95, pp. 794-803; 
Harrison, S.J., Quach, H., Link, E., A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma (2011) Blood, 118, pp. 6274-6283; 
Vogl, D.T., Raje, N.S., Jagannath, S., Ricolinostat (ACY-1215), the first selective HDAC6 inhibitor, in combination with bortezomib and dexamethasone in patients with relapsed or relapsed-and-refractory multiple myeloma: phase 1b results (ACY-100 study) (2015) Blood, 126, p. 1827; 
San-Miguel, J.F., Hungria, V.T.M., Yoon, S.-S., Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial (2014) Lancet Oncol, 15, pp. 1195-1206; 
Kyle, R.A., Rajkumar, S.V., Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma (2009) Leukemia, 23, pp. 3-9; 
Richardson, P.G., Hungria, V.T., Yoon, S.S., Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment (2016) Blood, 127, pp. 713-721; 
Mu, S., Kuroda, Y., Shibayama, H., Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma (2016) Eur J Clin Pharmacol, 72, pp. 153-161; 
Richardson, P.G., Lonial, S., Schlossman, R.L., Patient reported outcomes (PROs) of multiple myeloma (MM) patients treated with panobinostat (PAN) after >=2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled, PANORAMA-1 trial (2016) Proc Am Soc Clin Oncol, 34. , abstr 8054; 
Corso, A., Varettoni, M., Mangiacavalli, S., Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short-lived (2009) Eur J Haematol, 83, pp. 449-454; 
Dimopoulos, M.A., Lonial, S., White, D., Eloquent-2 update: a phase 3, randomized, open-label study of elotuzumab in combination with lenalidomide/dexamethasone in patients with relapsed/refractory multiple myeloma: 3-year safety and efficacy follow-up (2015) Blood, 126, p. 28; 
Stewart, A.K., Rajkumar, S.V., Dimopoulos, M.A., Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma (2015) N Engl J Med, 372, pp. 142-152; 
Moreau, P., Masszi, T., Grzasko, N., Ixazomib, an investigational oral proteasome inhibitor (PI), in combination with lenalidomide and dexamethasone (IRd), significantly extends progression-free survival (PFS) for patients (pts) with relapsed and/or refractory multiple myeloma (RRMM): the phase 3 TOURMALINE-MM1 study (2015) Blood, 126, p. 727; 
Anderson, K.C., Kyle, R.A., Rajkumar, S.V., Clinically relevant end points and new drug approvals for myeloma (2008) Leukemia, 22, pp. 231-239; 
Felix, J., Aragao, F., Almeida, J.M., Time-dependent endpoints as predictors of overall survival in multiple myeloma (2013) BMC Cancer, 13, p. 122; 
Richardson, P.G., Harvey, R.D., Laubach, J.P., Moreau, P., Lonial, S., San-Miguel, J.F., Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes (2016) Expert Rev Clin Pharmacol, 9, pp. 35-48; 
Moreau, P., Pylypenko, H., Grosicki, S., Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study (2011) Lancet Oncol, 12, pp. 431-440; 
Bringhen, S., Larocca, A., Rossi, D., Efficacy and safety of once-weekly bortezomib in multiple myeloma patients (2010) Blood, 116, pp. 4745-4753; 
San Miguel, J., Hungria, V.T., Yoon, S., Efficacy and safety based on duration of treatment of panobinostat plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma in the phase 3 panorama 1 study (2014) Blood, 124, p. 4742; 
Yee, A.J., Bensinger, W.I., Supko, J.G., Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial (2016) Lancet Oncol, , published online Sept 17
},
	month = {2016},
	pages = {e506 - e515},
	abstract = {Background Panobinostat plus bortezomib and dexamethasone significantly increased median progression-free survival compared with placebo plus bortezomib and dexamethasone in the phase 3 PANORAMA 1 trial. Here, we present the final overall survival analysis for this trial. Methods PANORAMA 1 is a randomised, placebo-controlled, double-blind, phase 3 trial of patients with relapsed or relapsed and refractory multiple myeloma with one to three previous treatments. Patients were randomly assigned (1:1) to receive panobinostat (20 mg orally) or placebo, with bortezomib (1{\textperiodcentered}3 mg/m2 intravenously) and dexamethasone (20 mg orally), over two distinct treatment phases. In treatment phase 1 (eight 3-week cycles), patients received: panobinostat or placebo on days 1, 3, 5, 8, 10, and 12; bortezomib on days 1, 4, 8, and 11; and dexamethasone on days 1, 2, 4, 5, 8, 9, 11, and 12. During treatment phase 2 (four 6-week cycles with a 2 weeks on, 1 week off schedule), panobinostat or placebo was given three times a week, bortezomib was administered once a week, and dexamethasone was given on the days of and following bortezomib administration. The primary endpoint was progression-free survival; overall survival was a key secondary endpoint. This study is registered at ClinicalTrials.gov, NCT01023308. Findings Between Jan 21, 2010, and Feb 29, 2012, 768 patients were enrolled into the study and randomly assigned to receive either panobinostat (n=387) or placebo (n=381), plus bortezomib and dexamethasone. At data cutoff (June 29, 2015), 415 patients had died. Median overall survival was 40{\textperiodcentered}3 months (95\% CI 35{\textperiodcentered}0{\textendash}44{\textperiodcentered}8) in those who received panobinostat, bortezomib, and dexamethasone versus 35{\textperiodcentered}8 months (29{\textperiodcentered}0{\textendash}40{\textperiodcentered}6) in those who received placebo, bortezomib, and dexamethasone (hazard ratio [HR] 0{\textperiodcentered}94, 95\% CI 0{\textperiodcentered}78{\textendash}1{\textperiodcentered}14; p=0{\textperiodcentered}54). Of patients who had received at least two previous regimens including bortezomib and an immunomodulatory drug, median overall survival was 25{\textperiodcentered}5 months (95\% CI 19{\textperiodcentered}6{\textendash}34{\textperiodcentered}3) in 73 patients who received panobinostat, bortezomib, and dexamethasone versus 19{\textperiodcentered}5 months (14{\textperiodcentered}1{\textendash}32{\textperiodcentered}5) in 74 who received placebo (HR 1{\textperiodcentered}01, 95\% CI 0{\textperiodcentered}68{\textendash}1{\textperiodcentered}50). Interpretation The overall survival benefit with panobinostat over placebo with bortezomib and dexamethasone was modest. However, optimisation of the regimen could potentially prolong treatment duration and improve patients{\textquoteright} outcomes, although further trials will be required to confirm this. Funding Novartis Pharmaceuticals. {\textcopyright} 2016 Elsevier Ltd},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84992694913\&doi=10.1016\%2fS2352-3026\%2816\%2930147-8\&partnerID=40\&md5=93e50c529318526d55c13247acc93d01},
	author = {San-Miguel, J.F. and Hungria, V.T.M. and Yoon, S.-S. and Beksac, M. and Dimopoulos, M.A. and Elghandour, A. and Jedrzejczak, W.W. and G{\"u}nther, A. and Nakorn, T.N. and Siritanaratkul, N. and Schlossman, R.L. and Hou, J. and Moreau, P. and Lonial, S. and Lee, J.H. and Einsele, H. and Sopala, M. and Bengoudifa, B.-R. and Binlich, F. and Richardson, P.G.}
}
